Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
Morbidity and mortality in patients suffering from systemic inflammatory response syndrome
(SIRS) remain high. The primary aim of the present study is to assess the efficacy of a
standardized 5% serum-protein solution containing immunoglobulins on serum cytokine levels.
The secondary aim is to evaluate survival of the patients.